"I thought there could be an easier way to make balloon arches for parties and special events," said an inventor, from ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

In our BTK degrader clinical program ... the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

Within the BTK market, we continue to strengthen ... In terms of zani, this is actually design as you pointed out, the third arm, which you mentioned is the combination of the tisle plus zanib ...

the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of ...

As Türkiye prepares to embrace 5G technologies, the contributions of Turkish engineers to the use of next-generation ...

Merit Medical Systems, Inc. MMSI, on Monday, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...